Biogen (BIIB) Operating Leases (2018 - 2025)
Historic Operating Leases for Biogen (BIIB) over the last 8 years, with Q4 2025 value amounting to $370.8 million.
- Biogen's Operating Leases fell 1190.31% to $370.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $370.8 million, marking a year-over-year decrease of 1190.31%. This contributed to the annual value of $370.8 million for FY2025, which is 1190.31% down from last year.
- According to the latest figures from Q4 2025, Biogen's Operating Leases is $370.8 million, which was down 1190.31% from $305.0 million recorded in Q3 2025.
- Biogen's 5-year Operating Leases high stood at $490.3 million for Q4 2023, and its period low was $274.2 million during Q2 2022.
- For the 5-year period, Biogen's Operating Leases averaged around $364.8 million, with its median value being $360.4 million (2021).
- Its Operating Leases has fluctuated over the past 5 years, first crashed by 2464.96% in 2022, then soared by 2431.19% in 2024.
- Over the past 5 years, Biogen's Operating Leases (Quarter) stood at $419.5 million in 2021, then rose by 2.55% to $430.2 million in 2022, then rose by 13.97% to $490.3 million in 2023, then decreased by 14.15% to $420.9 million in 2024, then decreased by 11.9% to $370.8 million in 2025.
- Its Operating Leases stands at $370.8 million for Q4 2025, versus $305.0 million for Q3 2025 and $310.9 million for Q2 2025.